In addition, Massi et al. [63] demonstrated in ex vivo experiments using glioma tissues and cells that CBD inhibits tumor growth by modulating the lipoxygenase (LOX) pathway and the endogenous cannabinoid system, whereas pretreatment with the 5-LOX-specific inhibitor MK-886 enhanced the antimitotic ability of CBD, suggesting that a combination of CBD and a 5-LOX inhibitor could enhance the effects of CBD.TRAIL acts with the corresponding receptor at the same time but also results in drug resistance, short plasma half-life, and other problems [64]. This evidence concerns the gene ALOX5 and central nervous system cancer.